BioClonetics Immunotherapeutics (2017)
About this raise
BioClonetics Immunotherapeutics, with a valuation of $10 million, is raising funds on Wefunder. The company is developing the first cure for HIV through the use of monoclonal antibodies. BioClonetics Immunotherapeutics has created a cell line that produces an anti-HIV antibody called Clone 3 that neutralizes all clades and groups of HIV isolates. The company is working with world-class laboratories and expects to complete animal trials within 18 to 24 months. Dr. Joseph Cotropia founded BioClonetics Immunotherapeutics in December 2009. The current crowdfunding campaign has a minimum target of $200,000 and a maximum target of $1 million. The campaign proceeds will be used for the production of the recombinant Clone 3 antibody, testing of the recombinant antibody against HIV isolates, initiation of animal trials, and completion of animal trials.
Investment Overview
Invested : $386,766
Deal Terms
- Platform
- Wefunder
- Start Date
- 04/11/2017
- Close Date
- 09/30/2017
$200,000
$1,000,000
$100
SAFE
RegCF
$10,000,000
30%
Company & Team
Company
- Year Founded
- 2009
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Location
- Heath, Texas
- Company Website
-
Visit Website
Team
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual